

**International Geneva
Directory of Swiss Global Health Actors**

Mymetics Corporation

www.mymetics.com/

Route de la Corniche 4 | CH-1066 Epalinges

Tel +41 21 653 45 35 | Fax +41 21 653 24 73 | mail: info@mymetics.com

BACKGROUND AND MISSION

Mymetics Corporation is a US registered biotechnology company with its main office in Switzerland which was founded in 2000. Mymetics' goal is to make lasting contributions to research and development in next-generation mucosal- and virosomes-based vaccines. The company is focused on developing these preventative vaccines. Mymetics concentrates its energies on research and development in regards to HIV/Aids, Malaria, influenza, Chikungunya virus, Herpes simplex virus and Respiratory Syncytial Virus (RSV).

AREAS OF INTEREST

- Vaccines
- HIV/Aids
- Malaria
- Influenza
- Respiratory Syncytial Virus (RSV)
- Chikungunya
- Oncology and Immunotherapy

HEALTH-RELATED ACTIVITIES

Mymetics uses two main scientific approaches in the conduction of its research. The first contains the use of virosomes as a new vaccine delivery platform that does not use live attenuated or killed pathogens. Secondly, Mymetics focuses research on the mucosal layer to prevent viruses from entering the blood stream. These scientific approaches allow Mymetics scientists to better understand how to construct stronger defences against viruses upon their entry into the blood stream. The goal of using influenza virosomes (in HIV/Aids, Influenza and Malaria vaccine) is to develop muscosal and blood antibodies, therefore stopping the virus at the point of entry.

GOVERNANCE AND STAFF

Mymetics is overseen by a 3 member board. The management team is led by President, CEO and CFO, Ronald Kempers. Governance also includes a 3 member Scientific Advisory Board as well as a 3 member board of directors.

FUNDING SOURCES AND BUDGET

Mymetics is a publicly traded company, which is registered in the United States on the OTC QB Venture Market, whereas 55% of the company are held by executives and board members. It is primarily funded through research and development services as well as grants

by the Bill and Melinda Gates Foundation, PATH Malaria Venture Initiative and Horizon 2020 - EU and Swiss Confederation, among others. Total assets as of end of 2017 were EUR 8 million.

PUBLICATIONS

For investor-related publications such as annual and quarterly reports, see:
www.mymetics.com/investors

For press releases, scientific publications and company presentations, see:
<https://www.mymetics.com/media-center/>

Last update: 13.08.2019